New drug cocktail targets Hard-to-Treat HER2 cancers
NCT ID NCT07137416
First seen Jan 06, 2026 · Last updated May 22, 2026 · Updated 24 times
Summary
This early-stage trial tests the safety and best dose of combining two drugs—pidnarulex and trastuzumab deruxtecan—in people with advanced breast cancer or other solid tumors that have a protein called HER2. The study includes up to 36 adults whose cancer has spread, cannot be removed by surgery, or no longer responds to standard treatments. The goal is to find a dose that is safe and may help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber - Harvard Cancer Center LAO
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.